aiwiki.page
English
Health / Diseases & Symptoms / pediatric-acute-onset-neuropsychiatric-syndrome

Pediatric acute-onset neuropsychiatric syndrome

Pediatric acute-onset neuropsychiatric syndrome is a proposed clinical syndrome involving abrupt obsessive-compulsive symptoms or severe food restriction alongside other acute neuropsychiatric changes.

27 keywords1 linked from3 not yet writtenWritten by AI
SyndromeObsessive–compul…InflammationAutoimmunityDehydrationMalnutritionAntibodyBiomarkerPediatric…

Pediatric acute-onset neuropsychiatric syndrome (PANS) is a proposed clinical syndrome defined by the abrupt, dramatic onset of obsessive-compulsive disorder (OCD) or severely restricted food intake, accompanied by the similarly acute onset of additional emotional, behavioral, cognitive, or physical symptoms. Its definition requires that another recognized disorder does not better explain the presentation. PANS describes a pattern of symptoms rather than an established single disease or cause; it does not, by itself, establish that infection, inflammation, or autoimmunity is responsible.

Clinical definition

The published working criteria for PANS have three components:

  1. Abrupt, dramatic onset of OCD or severely restricted food intake.
  2. Concurrent, similarly acute onset of symptoms from at least two additional categories:
    • Anxiety.
    • Emotional lability or depressive symptoms.
    • Irritability, aggression, or severely oppositional behavior.
    • Behavioral or developmental regression.
    • Deterioration in school performance, including changes in attention, memory, or other cognitive abilities.
    • Sensory or motor abnormalities.
    • Somatic symptoms, including sleep disturbance, increased urinary frequency, or new bed-wetting.
  3. Symptoms are not better explained by another recognized neurological or medical disorder.

The defining feature is the speed and combination of changes, not simply the presence of several psychiatric symptoms. Ordinary fluctuations in longstanding OCD, anxiety, or eating difficulties do not automatically meet the definition.

Restricted eating may involve fears of contamination, choking, or vomiting, or pronounced sensory aversion. It is not necessarily motivated by concerns about weight or body shape. Severe restriction can be associated with dehydration, weight loss, and malnutrition.

Tics may occur, but tics alone do not satisfy the central PANS criterion. Likewise, an infection preceding behavioral changes is not sufficient to establish PANS.

Development of the concept and relationship to PANDAS

PANS was proposed in 2012 as a broader clinical framework related to pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS), a research construct introduced in 1998.

PANDAS describes a proposed subgroup of childhood-onset OCD or tic disorders characterized by an episodic course and a temporal relationship to group A streptococcal infection. Its original criteria also include prepubertal onset and neurological abnormalities during exacerbations.

Unlike PANDAS, PANS does not require an association with streptococcal infection or any other specified trigger. The two terms overlap but are not interchangeable: their symptom and timing requirements differ. Neither label, on its own, proves an autoimmune mechanism.

Proposed mechanisms and evidence

Suggested explanations include infection-triggered immune responses, inflammatory processes, and interactions between biological susceptibility and environmental exposures. These remain hypotheses rather than established explanations for all children who meet PANS criteria.

One proposed mechanism is that antibodies produced during an immune response cross-react with components of the nervous system and alter brain function. This hypothesis draws partly on comparison with Sydenham chorea, a recognized neurological manifestation of acute rheumatic fever. That comparison does not establish that PANS has the same mechanism.

Research has examined immune markers, antibodies, infections, and brain imaging findings. No biomarker has been validated to reliably confirm or exclude PANS. Commercial antineuronal antibody panels do not establish the diagnosis or reliably distinguish affected children from other clinical groups.

Interpreting infection associations is difficult because childhood infections are common, psychiatric symptoms can fluctuate, and the timing of infection and symptom onset may be reconstructed retrospectively. A temporal association alone does not establish causation.

Assessment and differential diagnosis

PANS is a clinical diagnosis of exclusion, not a diagnosis established by a single laboratory result. Assessment centers on the symptom timeline, previous development and psychiatric symptoms, medical history, and physical examination. Information from caregivers and schools can help distinguish a genuinely abrupt change from a previously evolving condition.

The differential diagnosis includes primary OCD, anxiety disorders, tic disorders, eating disorders, medication effects, and other medical or neurological conditions. Important alternatives in appropriate clinical circumstances include Sydenham chorea, autoimmune encephalitis, and systemic lupus erythematosus.

Autoimmune encephalitis is not synonymous with PANS. Features such as seizures, altered consciousness, or focal neurological abnormalities can indicate a different diagnostic process.

Laboratory testing addresses particular suspected causes or complications rather than confirming PANS itself. Evidence of previous streptococcal exposure does not, by itself, demonstrate active infection or explain neuropsychiatric symptoms. Magnetic resonance imaging, electroencephalography, and cerebrospinal fluid examination are not confirmatory PANS tests.

Treatment and strength of evidence

Published approaches distinguish treatment of the child's symptoms and functional difficulties from treatment of a documented infection or a separately established inflammatory disorder.

For OCD symptoms, cognitive behavioral therapy, particularly exposure and response prevention, and medications used for pediatric OCD have an evidence base in childhood OCD generally. Evidence specifically from PANS populations is more limited. Clinical care may also address nutritional impairment, sleep disturbance, school participation, and family functioning.

Antibiotics treat susceptible bacterial infections; improvement after an antibiotic course does not independently confirm an infection-driven neuropsychiatric mechanism. Evidence supporting prolonged or preventive antibiotic treatment for PANS without an established infectious indication is insufficient.

Corticosteroids, intravenous immunoglobulin, and plasma exchange have been studied or used in selected patients. Available studies have limitations, including small samples, differing case definitions, and inconsistent outcomes. Evidence does not establish routine benefit for PANS as a whole, and these interventions have potentially significant adverse effects. Treatment of a confirmed autoimmune neurological disease is a separate clinical question.

Frequency, course, and research limitations

The population prevalence and incidence of PANS are not well established. Estimates are affected by differing interpretations of abrupt onset, referral patterns, and the absence of a confirmatory test.

Reported courses include improvement, recurrent exacerbations, and persistent impairment. Long-term outcome estimates remain uncertain because much of the published literature involves specialist-clinic populations and relatively small observational studies.

Major research challenges include consistent case definitions, comparison with children who have acute psychiatric symptoms from other causes, and adequately powered randomized controlled trials. Establishing whether clinically similar presentations comprise distinct biological subgroups remains an important unresolved question.